The Global Circulating Tumor Cells Market was valued at US$ 9.5 billion in 2023 and is projected to surpass the market size of US$ 19.0 billion by 2032 at a CAGR of 8.06% during the forecast period 2024–2032.
Global Liposome Development Service Market was valued at US$ 2,322.9 million in 2023 and is projected to attain a market size of US$ 5,016.0 million by 2032 at a CAGR of 8.93% during the forecast period 2024–2032.
Global Clinical Trials Support Service Market was valued at US$ 25.2 billion in 2023 and is projected to surpass US$ 47.1 billion by 2032 at a CAGR of 7.22% during the forecast period 2024–2032.
The Global Hand, Foot, and Mouth Disease Treatment Market was valued at US$ 3,037.3 million in 2023 and is projected to generate a revenue of US$ 5,175.1 million by 2032 at a CAGR of 6.1% during the forecast period 2024–2032.
Global plant stem cells market was valued at US$ 371.4 million in 2022 and is projected to attain a valuation of US$ 801.9 million by 2031 at a CAGR of 8.93% during the forecast period 2023-2031.
U.S. liquid biopsy market was valued at US$ 3,786.2 million in 2023 and is projected to surpass a market valuation of US$ 12,004.9 million by 2032 at a CAGR of 13.68% during the forecast period 2024–2032.
The global deuterated drugs market, valued at US$ 334.0 million in 2023, presents a robust growth pattern. With a projected valuation of US$ 871.8 million by 2032 at a CAGR of 11.25%, the market is driven by primary drugs including Austedo and Zepsun, used to treat Huntington's Disease (HD), Tardive Dyskinesia (TD), Cancer, and others.
Global Newcastle Disease Vaccine Market was valued at US$ 314.0 million in 2023 and is projected to surpass a valuation of US$ 458.6 million by 2032 at a CAGR of 4.3% During the Forecast Period 2024–2032.
Southeast Asia Olmesartan Market was valued at US$ 335.2 million in 2023 and is projected to surpass a valuation of US$ 518.8 million by 2032 at a CAGR of 4.3% during the forecast period 2024–2032.
Latin America insulin market was valued at US$ 2,855.1 million in 2022 and is projected to attain a valuation of US$ 3,857.50 million by 2031 at a CAGR of 3.4% during the forecast period 2023–2031.